Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma ; volume:9 ; number:5 ; year:2020 ; pages:583-595
Liver cancer ; 9, Heft 5 (2020), 583-595
- Creator
-
Ueshima, Kazuomi
Ogasawara, Sadahisa
Ikeda, Masafumi
Yasui, Yutaka
Terashima, Takeshi
Yamashita, Tatsuya
Obi, Shuntaro
Sato, Shinpei
Aikata, Hiroshi
Ohmura, Takumi
Kuroda, Hidekatsu
Ohki, Takamasa
Nagashima, Kengo
Ooka, Yoshihiko
Takita, Masahiro
Kurosaki, Masayuki
Chayama, Kazuaki
Kaneko, Shuichi
Izumi, Namiki
Kato, Naoya
Kudo, Masatoshi
Omata, Masao
- DOI
-
10.1159/000508724
- URN
-
urn:nbn:de:101:1-2020100102252642780294
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:56 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ueshima, Kazuomi
- Ogasawara, Sadahisa
- Ikeda, Masafumi
- Yasui, Yutaka
- Terashima, Takeshi
- Yamashita, Tatsuya
- Obi, Shuntaro
- Sato, Shinpei
- Aikata, Hiroshi
- Ohmura, Takumi
- Kuroda, Hidekatsu
- Ohki, Takamasa
- Nagashima, Kengo
- Ooka, Yoshihiko
- Takita, Masahiro
- Kurosaki, Masayuki
- Chayama, Kazuaki
- Kaneko, Shuichi
- Izumi, Namiki
- Kato, Naoya
- Kudo, Masatoshi
- Omata, Masao
Other Objects (12)
Prioritized Requirements for First-Line Systemic Therapy for Hepatocellular Carcinoma: Broad Benefit with Less Toxicity
Selection of Systemic Treatment Regimen for Unresectable Hepatocellular Carcinoma: Does Etiology Matter?
Newly Developed Modified ALBI Grade Shows Better Prognostic and Predictive Value for Hepatocellular Carcinoma
A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion
Adjuvant Immunotherapy after Curative Treatment for Hepatocellular Carcinoma
Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma
Combination Immunotherapy with Anti-PD-1/PD-L1 Antibody plus Anti-VEGF Antibody May Promote Cytotoxic T Lymphocyte Infiltration in Hepatocellular Carcinoma, Including in the Noninflamed Subclass
Implications of the TACTICS Trial: Establishing the New Concept of Combination/Sequential Systemic Therapy and Transarterial Chemoembolization to Achieve Synergistic Effects
Contrast harmonic imaging in the diagnosis and treatment of hepatic tumors
Hepatocellular carcinoma 2009 and beyond : 25 tables
Viral hepatitis A to E : an update in 2010 ; 14 tables
Prioritized Requirements for First-Line Systemic Therapy for Hepatocellular Carcinoma: Broad Benefit with Less Toxicity
Selection of Systemic Treatment Regimen for Unresectable Hepatocellular Carcinoma: Does Etiology Matter?
Newly Developed Modified ALBI Grade Shows Better Prognostic and Predictive Value for Hepatocellular Carcinoma
A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion
Adjuvant Immunotherapy after Curative Treatment for Hepatocellular Carcinoma
Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma
Combination Immunotherapy with Anti-PD-1/PD-L1 Antibody plus Anti-VEGF Antibody May Promote Cytotoxic T Lymphocyte Infiltration in Hepatocellular Carcinoma, Including in the Noninflamed Subclass
Implications of the TACTICS Trial: Establishing the New Concept of Combination/Sequential Systemic Therapy and Transarterial Chemoembolization to Achieve Synergistic Effects
Contrast harmonic imaging in the diagnosis and treatment of hepatic tumors
Hepatocellular carcinoma 2009 and beyond : 25 tables
Viral hepatitis A to E : an update in 2010 ; 14 tables
Prioritized Requirements for First-Line Systemic Therapy for Hepatocellular Carcinoma: Broad Benefit with Less Toxicity
Selection of Systemic Treatment Regimen for Unresectable Hepatocellular Carcinoma: Does Etiology Matter?
Newly Developed Modified ALBI Grade Shows Better Prognostic and Predictive Value for Hepatocellular Carcinoma
A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion
Adjuvant Immunotherapy after Curative Treatment for Hepatocellular Carcinoma
Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma
Combination Immunotherapy with Anti-PD-1/PD-L1 Antibody plus Anti-VEGF Antibody May Promote Cytotoxic T Lymphocyte Infiltration in Hepatocellular Carcinoma, Including in the Noninflamed Subclass
Implications of the TACTICS Trial: Establishing the New Concept of Combination/Sequential Systemic Therapy and Transarterial Chemoembolization to Achieve Synergistic Effects
Contrast harmonic imaging in the diagnosis and treatment of hepatic tumors
Hepatocellular carcinoma 2009 and beyond : 25 tables